Venous Thromboembolism: Classification, Risk Factors, Diagnosis, and Management
暂无分享,去创建一个
[1] B. Eriksson,et al. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. , 2007, Thrombosis research.
[2] P. Reitsma,et al. Genetics of venous thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.
[3] F. Rosendaal,et al. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis , 2002, British journal of haematology.
[4] S. Daeschner. Pulmonary embolism. , 1988, Nursing.
[5] J. Slattery,et al. Thigh-Length Versus Below-Knee Stockings for Deep Venous Thrombosis Prophylaxis After Stroke , 2010, Annals of Internal Medicine.
[6] J. Eikelboom,et al. Latest medical treatment strategies for venous thromboembolism , 2007, Expert opinion on pharmacotherapy.
[7] L. Mazzolai,et al. Comparison of the diagnostic performance of the original and modified Wells score in inpatients and outpatients with suspected deep vein thrombosis. , 2011, Thrombosis research.
[8] H. Partsch,et al. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. , 2000, Journal of vascular surgery.
[9] G. Raskob,et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial , 2010, The Lancet.
[10] D. W. Barritt,et al. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. , 1960, Lancet.
[11] S. Frostick,et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial , 2007, Journal of thrombosis and haemostasis : JTH.
[12] Kevin Weiss,et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. , 2017, Annals of internal medicine.
[13] V. Laux,et al. Rivaroxaban: A New Oral Factor Xa Inhibitor , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[14] J. Eikelboom,et al. Update on Antithrombotic Therapy: New Anticoagulants , 2010, Circulation.
[15] J. Vandenbroucke,et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis , 1995, The Lancet.
[16] D. Wheatley,et al. Venous thromboembolism prophylaxis guideline implementation is improved by nurse directed feedback and audit , 2011, Thrombosis journal.
[17] M. Prins,et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: A randomized, controlled trial , 2005 .
[18] S. Schoenberg,et al. Venous thromboembolism: additional diagnostic value and radiation dose of pelvic CT venography in patients with suspected pulmonary embolism. , 2011, European journal of radiology.
[19] Joseph A. Caprini. Mechanical Methods for Thrombosis Prophylaxis , 2010, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[20] E. Devine,et al. Compression stockings to prevent post-thrombotic syndrome: a role for anticoagulation clinics? , 2007, Journal of Thrombosis and Thrombolysis.
[21] M. Gent,et al. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double‐blind comparison , 2007, Journal of thrombosis and haemostasis : JTH.
[22] P. Mannucci,et al. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. , 1996, Blood.
[23] G. Raskob,et al. Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement , 2001, Circulation.
[24] P. Sandercock,et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial , 2009, The Lancet.
[25] M. O’Donnell,et al. Graduated compression stockings to prevent venous thromboembolism in hospital: evidence from patients with acute stroke. , 2011, Polskie Archiwum Medycyny Wewnetrznej.
[26] Pamela K Woodard,et al. Multidetector computed tomography for acute pulmonary embolism. , 2006, The New England journal of medicine.
[27] W. K. Ho. Deep vein thrombosis--risks and diagnosis. , 2010, Australian family physician.
[28] G. Raskob,et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. , 2010, The New England journal of medicine.
[29] C. Mélot,et al. Comparison of the Wells score with the simplified revised Geneva score for assessing pretest probability of pulmonary embolism. , 2011, Thrombosis research.
[30] J. Hirsh,et al. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[31] S. Frostick,et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial , 2007, The Lancet.
[32] B. Eriksson,et al. Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement , 2006, Journal of thrombosis and haemostasis : JTH.
[33] Masaaki Ito,et al. High Plasma Level of Factor VIII , 2011 .
[34] C. O. Kennedy. A controlled trial , 1971, British Homeopathic Journal.
[35] C. Kearon,et al. Natural History of Venous Thromboembolism , 2003, Circulation.
[36] J. Heit,et al. Risk factors for venous thromboembolism. , 2003, Clinics in chest medicine.
[37] P. Monagle,et al. Post-thrombotic syndrome , 2002, Archives of disease in childhood.
[38] P. Wells,et al. Diagnosis and treatment of deep-vein thrombosis , 2006, Canadian Medical Association Journal.
[39] M. Gent,et al. BAY 59‐7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose‐ranging study , 2005, Journal of thrombosis and haemostasis : JTH.
[40] H. Büller,et al. Fondaparinux or enoxaparin for initial treatment of symptomatic deep venous thrombosis: Randomized trial , 2004 .
[41] D. Maclellan,et al. MECHANICAL COMPRESSION IN THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM , 2007, ANZ journal of surgery.
[42] Graeme J. Hankey. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial , 2009 .
[43] Janet B. Long. Venous Thromboembolism: Pharmacological and Nonpharmacological Interventions , 2009, The Journal of cardiovascular nursing.
[44] Janis Bormanis,et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management , 1997, The Lancet.
[45] J. Douketis,et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. , 1998, JAMA.
[46] D. Aujesky,et al. Comparison of the revised Geneva score with the Wells rule for assessing clinical probability of pulmonary embolism , 2007, Journal of thrombosis and haemostasis : JTH.
[47] M. Prins,et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study , 2008, Journal of thrombosis and haemostasis : JTH.
[48] P. Romundstad,et al. Incidence and mortality of venous thrombosis: a population‐based study , 2007, Journal of thrombosis and haemostasis : JTH.
[49] J. Heit. Venous thromboembolism: disease burden, outcomes and risk factors , 2005, Journal of thrombosis and haemostasis : JTH.
[50] Sfedu Ep,et al. [Acute pulmonary embolism. I]. , 2010, Cardiologia pratica.
[51] M Gent,et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. , 2003, The New England journal of medicine.
[52] Arnaud Perrier,et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. , 2008, Archives of internal medicine.
[53] M. Prins,et al. Below-Knee Elastic Compression Stockings To Prevent the Post-Thrombotic Syndrome , 2004, Annals of Internal Medicine.
[54] S. Eichinger,et al. Novel Anticoagulants for the Prevention and Treatment of Venous Thromboembolism , 2003, Wiener Medizinische Wochenschrift.
[55] T. Muneta,et al. Doppler ultrasonography-aided early diagnosis of venous thromboembolism after total knee arthroplasty. , 2010, European Journal of Vascular and Endovascular Surgery.
[56] A. Spyropoulos. Managing Oral Anticoagulation Requires Expert Experience and Clinical Evidence , 2006, Journal of Thrombosis and Thrombolysis.
[57] R. Clarke,et al. Homocysteine, MTHFR and risk of venous thrombosis: a meta‐analysis of published epidemiological studies , 2005, Journal of thrombosis and haemostasis : JTH.
[58] Jonathan Dreyer,et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. , 2003, The New England journal of medicine.
[59] H. Bounameaux,et al. Diagnosis of venous thromboembolism: an update , 2010, Vascular medicine.
[60] L. Kwong. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty. , 2011, The American journal of managed care.
[61] B. Eriksson,et al. A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement , 2006, Circulation.